(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, provides a strategic update of its LDOS47 clinical program. 20181113-HBP-Press-Release-Clinical-Study-Update.pdf
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will initiate a new clinical program in pancreatic cancer which will be led by Dr. Daniel D. Von Hoff. Dr. Von Hoff is […]
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD342,000. 20181030-HBP-Press-Release-Closes-Private-Placement-FINAL.pdf
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2018. 20181026-HBP-Press-Release-Announces-Fiscal-2018-Results-FINAL.pdf
RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to extend the exercise period of a total of 4,546,000 outstanding common […]
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has extended its collaboration agreement with Moffitt Cancer Center for an additional year. 20181010-HBP-Press-Release-Moffitt-Collaboration-L-DOS47-Immunotherapy-FINAL.pdf
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Safety Review Committee (“SRC”) reviewed safety data from the fifth dosing cohort of the Company’s LDOS001 study and recommended that Helix begin enrollment of […]
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX:HBP), (FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that its collaborator ProMab Biotechnologies, Inc. (“ProMab”) paper entitled ‘CAR-T cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth’ is published in Cancers – […]
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD456,000. 20180910-HBP-Press-Release-Closes-Private-Placement-FINAL.pdf
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that its collaborator ProMab Biotechnologies, Inc. (“ProMab”) will present at the CAR-TCR Summit 2018 being held from September 4th – 7th, 2018 in Boston, Massachusetts. […]